A nanoplasmonic biosensor for the precise detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by leveraging advances in nanostructured sensing materials and highly selective monoclonal antibodies is presented. The sensor integrates plasmonic Au nanostructures optimized for surface-enhanced Raman scattering (SERS), enhancing sensitivity through unique light interactions at the nanoscale. Coupled with exclusive antibodies that specifically target SARS-CoV-2 and its evolving variants, this sensor demonstrates remarkable selectivity and versatility. Validated with 270 clinical samples, it demonstrates a sensitivity of 98.9% and specificity of 100%. More importantly, the virus in nasopharyngeal swab samples collected over 3 years, marking the long-term, large-scale clinical validation of the nanoplasmonic biosensor for SARS-CoV-2 is been successfully detected. Furthermore, the integration of this sensor with face masks enables the detection of airborne SARS-CoV-2, highlighting its potential for routine management of coronavirus disease 2019 (COVID-19).

中文翻译：

---

使用高亲和力单克隆抗体和等离子体纳米结构推进 SARS-CoV-2 变体检测


提出了一种纳米等离子体生物传感器，用于利用纳米结构传感材料和高选择性单克隆抗体的进步来精确检测严重急性呼吸系统综合症冠状病毒 2 （SARS-CoV-2）。该传感器集成了针对表面增强拉曼散射 （SERS） 优化的等离子体 Au 纳米结构，通过纳米级独特的光相互作用提高了灵敏度。结合专门针对 SARS-CoV-2 及其不断发展的变体的独家抗体，该传感器表现出卓越的选择性和多功能性。经 270 个临床样本验证，其灵敏度为 98.9%，特异性为 100%。更重要的是，3 年多来收集的鼻咽拭子样本中的病毒，标志着 SARS-CoV-2 纳米等离子体生物传感器的长期、大规模临床验证被成功检测到。此外，该传感器与口罩的集成能够检测空气传播的 SARS-CoV-2，凸显了其在 2019 冠状病毒病 （COVID-19） 常规管理方面的潜力。